Cue Biopharma, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cue Biopharma, Inc. on October 7, 2019, covering events that occurred on October 3, 2019. The filing primarily addresses significant changes in executive leadership and the execution of amended employment agreements.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only specific financial figures disclosed relate to executive compensation:
- Signing Bonus: $130,000 (net after-tax basis) awarded to Anish Suri.
- Equity Grants (Anish Suri): 400,000 stock options and 100,000 restricted stock units (RSUs).
- Future Equity Grant (Anish Suri): Not less than 50,000 RSUs scheduled for March 31, 2020.
Material Changes
The filing reports the following material changes in corporate governance and executive roles:
- Appointment of President: Anish Suri, previously Chief Scientific Officer (CSO) and Senior Vice President, was appointed President and CSO.
- Role Change for CEO: Daniel Passeri's title was changed from President and Chief Executive Officer (CEO) to CEO only, following his resignation as President.
- Compensation Agreements: Both executives entered into amended employment agreements on October 3, 2019, which include provisions for additional severance benefits and potential acceleration of equity awards upon certain termination events.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, financial outlook, or management commentary regarding business strategy. The primary risk disclosed relates to the potential financial impact of the new severance provisions and equity acceleration clauses included in the amended executive employment agreements.
Investor Verification Checklist
- Verify the specific terms of the "certain termination events" that trigger severance and equity acceleration in the Suri and Passeri agreements (Exhibits 10.1 and 10.2).
- Confirm the vesting schedules and exercise prices for the 400,000 stock options and 150,000 total RSUs granted to Anish Suri.
- Review the company's cash position to assess the immediate impact of the $130,000 signing bonus and future equity dilution.
- Monitor subsequent filings for any further changes to the executive leadership structure.